PortalPublikationenLong-term survival of patients with CLL after allogeneic tra...

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation

Standard

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. / van Gelder, M; de Wreede, L C; Bornhäuser, M; Niederwieser, D; Karas, M; Anderson, N S; Gramatzki, M; Dreger, P; Michallet, M; Petersen, E; Bunjes, D; Potter, M; Beelen, D; Cornelissen, J J; Yakoub-Agha, I; Russell, N H; Finke, J; Schoemans, H; Vitek, A; Urbano-Ispízua, Á; Blaise, D; Volin, L; Chevallier, P; Caballero, D; Putter, H; van Biezen, A; Henseler, A; Schönland, S; Kröger, N; Schetelig, J.

in: BONE MARROW TRANSPL, Jahrgang 52, Nr. 3, 03.2017, S. 372-380.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

van Gelder, M, de Wreede, LC, Bornhäuser, M, Niederwieser, D, Karas, M, Anderson, NS, Gramatzki, M, Dreger, P, Michallet, M, Petersen, E, Bunjes, D, Potter, M, Beelen, D, Cornelissen, JJ, Yakoub-Agha, I, Russell, NH, Finke, J, Schoemans, H, Vitek, A, Urbano-Ispízua, Á, Blaise, D, Volin, L, Chevallier, P, Caballero, D, Putter, H, van Biezen, A, Henseler, A, Schönland, S, Kröger, N & Schetelig, J 2017, 'Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation', BONE MARROW TRANSPL, Jg. 52, Nr. 3, S. 372-380. https://doi.org/10.1038/bmt.2016.282

APA

van Gelder, M., de Wreede, L. C., Bornhäuser, M., Niederwieser, D., Karas, M., Anderson, N. S., Gramatzki, M., Dreger, P., Michallet, M., Petersen, E., Bunjes, D., Potter, M., Beelen, D., Cornelissen, J. J., Yakoub-Agha, I., Russell, N. H., Finke, J., Schoemans, H., Vitek, A., ... Schetelig, J. (2017). Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. BONE MARROW TRANSPL, 52(3), 372-380. https://doi.org/10.1038/bmt.2016.282

Vancouver

van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS et al. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. BONE MARROW TRANSPL. 2017 Mär;52(3):372-380. https://doi.org/10.1038/bmt.2016.282

Bibtex

@article{82ab9140cb644c85b3f2c844da35fb05,
title = "Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation",
abstract = "Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.",
keywords = "Journal Article",
author = "{van Gelder}, M and {de Wreede}, {L C} and M Bornh{\"a}user and D Niederwieser and M Karas and Anderson, {N S} and M Gramatzki and P Dreger and M Michallet and E Petersen and D Bunjes and M Potter and D Beelen and Cornelissen, {J J} and I Yakoub-Agha and Russell, {N H} and J Finke and H Schoemans and A Vitek and {\'A} Urbano-Isp{\'i}zua and D Blaise and L Volin and P Chevallier and D Caballero and H Putter and {van Biezen}, A and A Henseler and S Sch{\"o}nland and N Kr{\"o}ger and J Schetelig",
year = "2017",
month = mar,
doi = "10.1038/bmt.2016.282",
language = "English",
volume = "52",
pages = "372--380",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation

AU - van Gelder, M

AU - de Wreede, L C

AU - Bornhäuser, M

AU - Niederwieser, D

AU - Karas, M

AU - Anderson, N S

AU - Gramatzki, M

AU - Dreger, P

AU - Michallet, M

AU - Petersen, E

AU - Bunjes, D

AU - Potter, M

AU - Beelen, D

AU - Cornelissen, J J

AU - Yakoub-Agha, I

AU - Russell, N H

AU - Finke, J

AU - Schoemans, H

AU - Vitek, A

AU - Urbano-Ispízua, Á

AU - Blaise, D

AU - Volin, L

AU - Chevallier, P

AU - Caballero, D

AU - Putter, H

AU - van Biezen, A

AU - Henseler, A

AU - Schönland, S

AU - Kröger, N

AU - Schetelig, J

PY - 2017/3

Y1 - 2017/3

N2 - Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.

AB - Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.

KW - Journal Article

U2 - 10.1038/bmt.2016.282

DO - 10.1038/bmt.2016.282

M3 - SCORING: Journal article

C2 - 27941763

VL - 52

SP - 372

EP - 380

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 3

ER -